ReviewClinical and experimental immunology2013
Suppression, subversion and escape: the role of regulatory T cells in cancer progression.
Review in Clinical and experimental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.Cell communication and signaling : CCS · 2021Pooled it
- Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis.Oncotarget · 2017Pooled it
- Impact of oral administration of single strainFrontiers in immunology · 2022Trial
- Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer.Clinical and experimental immunology · 2019Trial
- Rho GTPase-related prognostic signature for esophageal squamous cell carcinoma identifies CTTN as a candidate adverse prognostic marker.Molecular biology reports · 2026Article
- Review
- Identification of the gene signatures related to NK/T cell communication to evaluate the tumor microenvironment and prognostic outcomes of patients with prostate adenocarcinoma.Frontiers in immunology · 2025Article
- Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products.Frontiers in immunology · 2025Review
- Ruthenium-dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation.Cancer chemotherapy and pharmacology · 2024Article
- Immunomodulatory effects of iTr35 cell subpopulation and its research progress.Clinical and experimental medicine · 2024Review
- Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.Cancer cell international · 2023Review
- In-vitro model to mimic T cell subset change in human PDAC organoid co-culture.Journal of cancer research and clinical oncology · 2023Article
- HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.Cancer cell international · 2023Article
- CCR4 Blockade Diminishes Intratumoral Macrophage Recruitment and Augments Survival of Syngeneic Pancreatic Cancer-Bearing Mice.Biomedicines · 2023Article
- Association between multiple sclerosis and prostate cancer risk: A systematic review and meta‑analysis.Oncology letters · 2023Article
- Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases.Frontiers in oncology · 2023Review
- Article
- TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma.Biomedicines · 2022Article
- The role of interleukin‑7 serum level as biological marker in breast cancer: a cross‑sectional, observational, and analytical study.World journal of surgical oncology · 2022Observational
- MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.Clinical and experimental immunology · 2022Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Regulatory T cells (T(regs) ) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self- and tumour-associated antigens, T(regs) are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti-tumour responses. Suppression mechanisms employed by T(regs) are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti-tumour responses. This review will focus on the current evidence supporting the central role of T(regs) in establishing tumour-specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of T(regs) accumulation within the tumour, including enhanced recruitment, in-situ or local proliferation, and de-novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of T(regs) . The role of T(regs) is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.